NYSEAMERICAN:HEB Hemispherx BioPharma (HEB) Stock Price, News & Analysis $6.70 -1.68 (-20.05%) As of 06/13/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Hemispherx BioPharma Stock (NYSEAMERICAN:HEB) Get Hemispherx BioPharma alerts:Sign Up Key Stats Today's Range$5.80▼$9.0050-Day Range$6.70▼$6.7052-Week Range$1.69▼$14.81Volume7,639 shsAverage Volume102,599 shsMarket Capitalization$16.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Hemispherx BioPharma, Inc. (NYSEAMERICAN:HEB) is a U.S.-based biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of viral infections, cancers and immune system disorders. The company’s research centers on harnessing the body’s innate immune response to address diseases that currently lack broadly effective treatments. Hemispherx’s principal commercial product is Alferon N Injection, an antiviral drug indicated for the treatment of external genital warts. Its lead investigational candidate is Ampligen® (rintatolimod), a synthetic RNA molecule designed as a toll-like receptor 3 agonist. Ampligen has been studied in conditions such as chronic fatigue syndrome (myalgic encephalomyelitis) and certain malignancies, and the company continues to advance clinical programs and regulatory activities around this immune-modulating therapy. Headquartered in Philadelphia, Pennsylvania, Hemispherx BioPharma operates primarily in the United States while pursuing strategic collaborations and regulatory approvals internationally. The company is led by President and Chief Executive Officer Thomas G. Equels, under whose guidance Hemispherx engages with government agencies, academic research centers and commercial partners to support its pipeline and expand its therapeutic reach.AI Generated. May Contain Errors. Read More Receive HEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemispherx BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HEB Stock News HeadlinesHemispherx BioPharma (NYSEAMERICAN:HEB) Stock Passes Above 200-Day Moving Average - Time to Sell?September 23, 2025 | americanbankingnews.comHamilton ETFs Launches Hamilton Canadian Financials Index ETFJanuary 20, 2025 | businesswire.comAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone. | Porter & Company (Ad)H-E-B’s affordable grocery chain Joe V’s Smart Shop is coming to IrvingAugust 10, 2024 | dallasnews.comDHemispherx Biopharma earnings preview: what Wall Street is expectingMay 15, 2024 | markets.businessinsider.comH-E-B hosting hiring fairsJanuary 7, 2024 | cbsnews.comH-E-B bets on loyal customers as it expands affordable Joe V’s storesOctober 3, 2023 | chron.comH-E-B enters the film world with a five-part docuseries covering Texas parks and wildlifeAugust 28, 2023 | chron.comSee More Headlines HEB Stock Analysis - Frequently Asked Questions How have HEB shares performed this year? Hemispherx BioPharma's stock was trading at $0.2170 on January 1st, 2025. Since then, HEB shares have increased by 2,987.6% and is now trading at $6.70. How were Hemispherx BioPharma's earnings last quarter? Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) posted its quarterly earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.70) by $0.63. The specialty pharmaceutical company had revenue of $0.03 million for the quarter. When did Hemispherx BioPharma's stock split? Hemispherx BioPharma shares reverse split on Tuesday, June 11th 2019.The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Hemispherx BioPharma? Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hemispherx BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Goodrich Petroleum (GDPMQ), Biocept (BIOC), CTI BioPharma (CTIC), Inovio Pharmaceuticals (INO), Ayala Pharmaceuticals (ADXS). Company Calendar Last Earnings8/15/2019Today10/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:HEB Previous SymbolNYSE:HEB CIK946644 Webwww.hemispherx.net Phone+1-407-2718516FaxN/AEmployees31Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares2,442,000Free FloatN/AMarket Cap$16.36 million OptionableNot Optionable BetaN/A Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSEAMERICAN:HEB) was last updated on 10/2/2025 by MarketBeat.com Staff From Our Partners$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Biotech has a clinical approach that intrigues investorsThis biotech is gearing up for Phase 2 trials with a strategy to unlock multiple approvals from one study. ...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemispherx BioPharma, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemispherx BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEB Stock Alerts